Kyverna Therapeutics (KYTX)Deerfield Management Company, L.P. opened a new position $18.8M

2M

Shares reported

0.27%

Disclosed portfolio weight

$18.8M

Reported value

Holdings as of

Dec 31, 2025

Filed

Feb 17, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jan 8, 2026Company filing · Form 8-K · Results, Executive changeChanged a top executive or board member, and reported its results“On January 8, 2026, the Board appointed Christi Shaw, a current member of the Board, as the Company’s Executive Chairperson of the Board, effective January 12, 2026 (the “Effective Date”).”
2. Jan 29, 2026Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On January 29, 2026, Karen Walker notified Kyverna Therapeutics, Inc. (the “Company”) that she will be retiring from the Company and will cease to serve as the Company’s Chief Technology Officer, effective February 9, 2026.”

What came next

1. Feb 24, 2026Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On February 24, 2026, the board of directors (the “Board”) of Kyverna Therapeutics, Inc. (the “Company”) appointed Andrew Miller, Ph.D. as a Class III director of the Company, effective immediately.”
2. Mar 26, 2026Company filing · Form 8-K · ResultsReported its results
3. May 12, 2026Company filing · Form 8-K · ResultsReported its results
4. May 14, 2026Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On May 14, 2026, the Board of Directors (the “Board”) of Kyverna Therapeutics, Inc. (the “Company”) appointed Gregory Martini as the Company’s Chief Financial Officer, effective May 18, 2026 (the “Effective Date”).”

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Kyverna Therapeutics

OQRO holds no insider, Congress, fund or contract record for Kyverna Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its KYTX page.

How this filing works

• SEC Form 13F

Other disclosures at Kyverna Therapeutics

• SEC Form 13F-HRNov 14, 2024

Everything OQRO holds on this company is on its KYTX page.